Share class: Novo Nordisk A/S

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A101,074,872,00000 70.25 %
Stock B13,390,128,0003,136,580,984 ( 92.52 %) 48,091,207 ( 1.419 %)

Major shareholders: Novo Nordisk A/S

NameEquities%Valuation
Novo Holdings A/S (Investment Company)
5.610 %
190,183,000 5.610 % 26 476 M kr
Novo Nordisk A/S
0.3938 %
13,351,944 0.3938 % 1 859 M kr
State Street Global Advisors Ltd.
0.2214 %
7,505,704 0.2214 % 1 045 M kr
Sjunde AP-fonden
0.1370 %
4,643,506 0.1370 % 646 M kr
MFS International Singapore Pte Ltd.
0.1280 %
4,337,999 0.1280 % 604 M kr
Eleva Capital LLP
0.1278 %
4,331,421 0.1278 % 603 M kr
Eurizon Capital SGR SpA
0.1132 %
3,839,133 0.1132 % 534 M kr
FMR Investment Management (UK) Ltd.
0.1126 %
3,815,814 0.1126 % 531 M kr
Amundi Asset Management SA (Investment Management)
0.1101 %
3,732,665 0.1101 % 520 M kr
CAPFI DELEN Asset Management NV
0.1011 %
3,429,033 0.1011 % 477 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
Novo Holdings A/S (Investment Company)
100.00 %
1,074,872,000 100.00 % 150 B kr
ANIMA Sgr SpA
0.0270 %
290,732 0.0270 % 40 M kr
Creutz & Partners The Art of Asset Management SA
0.009303 %
100,000 0.009303 % 14 M kr
Kieger AG
0.002940 %
31,596 0.002940 % 4 M kr
Mercer Global Investments Europe Ltd.
0.002487 %
26,732 0.002487 % 4 M kr
OLZ AG
0.001913 %
20,557 0.001913 % 3 M kr
Carmignac Gestion Luxembourg SA (UK)
0.000186 %
2,000 0.000186 % 278 426 kr
Eurizon Capital SGR SpA
0.000009 %
99 0.000009 % 13 782 kr
NameEquities%Valuation
Jennison Associates LLC
0.6260 %
21,220,641 0.6260 % 2 953 M kr
Fidelity Management & Research Co. LLC
0.5750 %
19,494,642 0.5750 % 2 713 M kr
Merrill Lynch International
0.4320 %
14,644,337 0.4320 % 2 038 M kr
Eaton Vance Management
0.4310 %
14,610,900 0.4310 % 2 033 M kr
Fisher Asset Management LLC
0.3944 %
13,370,627 0.3944 % 1 861 M kr
Fayez Sarofim & Co.
0.3703 %
12,552,088 0.3703 % 1 747 M kr
Royal Trust Corp. of Canada
0.2997 %
10,161,527 0.2997 % 1 414 M kr
T. Rowe Price International Ltd.
0.2803 %
9,503,764 0.2803 % 1 323 M kr
Renaissance Technologies LLC
0.2704 %
9,165,374 0.2704 % 1 275 M kr
Loomis, Sayles & Co. LP
0.2625 %
8,897,437 0.2625 % 1 238 M kr
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional9.60%
Novo Nordisk A/S0.39%
Unknown90.01%

Based on 1000 largest holdings

Geographical origin of shareholders

Denmark 6.22%
United Kingdom 0.95%
Germany 0.31%
France 0.28%
Sweden 0.28%
Norway 0.26%
Italy 0.24%
Ireland 0.16%
Finland 0.14%
Singapore 0.13%
Switzerland 0.13%
Luxembourg 0.13%
Belgium 0.12%
Australia 0.12%
Netherlands 0.09%
United States 0.09%
Austria 0.07%
Spain 0.07%
Canada 0.06%
New Zealand 0.03%
Japan 0.02%
Slovenia 0.02%
Portugal 0.01%
Liechtenstein 0.01%
South Africa 0.01%
Iceland 0.01%
Hong Kong 0.01%

Based on 1000 largest holdings

Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
69,260
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW